Ionis Pharmaceuticals IONS Total Cost of Revenue
Total Cost of Revenue at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's total cost of revenue?
- Ionis Pharmaceuticals (IONS) reported total cost of revenue of $2.98M in Q1 2026.
- How has Ionis Pharmaceuticals's total cost of revenue changed year-over-year?
- Ionis Pharmaceuticals's total cost of revenue increased by 103.9% year-over-year, from $1.46M to $2.98M.
- What is the long-term trend for Ionis Pharmaceuticals's total cost of revenue?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's total cost of revenue has grown at a 10.1% compound annual growth rate (CAGR), from $10.84M to $15.91M.
- What does total cost of revenue mean?
- The direct costs incurred to produce the goods or services sold.
- How do you interpret total cost of revenue?
- An increase relative to revenue may indicate rising production costs or pricing pressure, while a decrease suggests improved operational efficiency.
- How does total cost of revenue compare across companies?
- Standard across all industries; biotech firms typically have lower costs of revenue compared to manufacturing firms due to the nature of royalty-based revenue models.